



**Supplementary Figure 1: Expression validation of Mock, PRA and PRB stable cell lines** . Western blot analysis of PRA, PRB, endogenous Juns (A), Fos (B), co-repressor proteins (C) and Cx43 in hTERT-HM stable cell lines developed in our laboratory.




**Supplementary Figure 2: Expression of AP-1 factors in human myometrium.** Term human myometrium from non-laboring and laboring state. Representative pictures of IHC for JUN and FOS proteins. Scale bar = 40  $\mu$ m.




**Supplementary Figure 3: Interaction between PRs and AP-1 proteins is P4 independent.**

In-situ proximity ligation assay (PLA) of PRs with Juns and Fos proteins. A) Representative pics, and B) signal analysis (average nuclear signals/cell from three fields). PRA and PRB stale transfected hTERT-HM cells were treated with vehicle for 2 h and then subjected to PLA analysis. Data represents mean  $\pm$  SD.  $n = 3$  experiments. Two way ANOVA followed by bonferroni posttests show significant differences between PRA and PRB in the interaction of cJUN ( $p < 0.001$ ), Fra1 ( $p < 0.001$ ) and Fra2 ( $p < 0.01$ ). Scale bar = 40  $\mu$ m.




**Supplementary Figure 4: Co-IP analysis confirms the differential associations between PR isoforms and Jun/Fos proteins.** SHM cells were transfected with PRA or PRB along with Jun or Fos expression vectors and treated with 100 nM P4. 250  $\mu$ g of nuclear lysates were then subjected to Co-IP with PR antibody, immune complex was resolved by SDS-PAGE and immunoblotting with respective Jun or Fos antibodies. 10% Input from the cell lysates is shown in the left panel. Shown are representative blots from two independent experiments.






**Supplementary Figure 6:** Validation of PRA and PRB expression in hTERT-HM<sup>A/B</sup> cell line induced with either DOX (25 ng/ml) or RSL (100 nM) or both for 24 h and stimulated with vehicle or P4 (100 nM) for additional 2 h. Total lysates were subjected to SDS-PAGE and immunoblotting. Tubulin was used as a loading control.




Supplementary Figure 7 A: Uncropped blots and replicates of Figure 5M.




Supplementary Figure 7 B: Uncropped blots or replicates of Supplementary Figure 1.





Supplementary Figure 7 C: Uncropped blots or replicates of Supplementary Figure 4.



Supplementary Figure 7. D: Uncropped blots and replicate of Supplementary Figure 6.

**Supplementary Table 1: Sources and working concentrations of antibodies used in this study**

ANTIGEN	ANTIBODY	WORKING CONCENTRATION $\mu\text{g/ml}$	SOURCE
cJUN	sc-376488	0.2	Santa Cruz
JUNB	sc-73	0.4	Santa Cruz
JUND	sc-74	0.4	Santa Cruz
cFOS	sc-52x	0.4	Santa Cruz
FOSB	sc-52926	0.2	Santa Cruz
FRA1	sc-271657	0.8	Santa Cruz
FRA2	sc-166102	0.4	Santa Cruz
p54 <sup>nrb</sup>	sc-166704	0.4	Santa Cruz
mSIN3A	sc-994	0.8	Santa Cruz
Cx43	AB1728	0.2	Millipore
PR	sc-7208	0.2	Santa Cruz
PRB	C1A2	0.2	Cell Sig.
P4	7720-0496	10	AbD Serotec
20 $\alpha$ HSD (AKR1C1)	ab183078	5	Abcam
Fibrillarlin	2639S	0.015	Cell Sig.
Tubulin	T5168	5	Sigma Aldrich